flow trial semaglutide kidney outcomes Media Centre Kidney and Survival Outcomes with

Electrolyte balance matters alongside hydration

Possible biases caused by the randomization process, deviations from intended interventions, missing data, outcome measurements, and selective reporting were rated as high risk, low risk, or some concerns

Thats particularly true when it comes to the global weight-loss drug market, which Wall Street analysts project will reach $150 billion within the next decade

Bottom line Zepbound is FDA approved as a weight loss drug and to treat mild to moderate obstructive sleep apnea

The maximum dose of semaglutide for obesity is 2.4 mg weekly in the current guidelines

doi: 10.3389/fphar.2024.1412245 Received 04 April 2024 Accepted 24 June 2024 Published 18 July 2024 Volume 15 - 2024 Edited by Irina Ielciu, University of Medicine and Pharmacy Iuliu Hatieganu, Romania Reviewed by Javad Mottaghipisheh, Swedish University of Agricultural Sciences, Sweden Shaymaa Mahmoud, University of Menoufia, Egypt Ufuk Koca alilkan, Gazi University, Trkiye Aida Abd El-Wahed, Agricultural Research Center, Egypt Gandhi Radis Baptista, Federal University of Ceara, Brazil Updates Copyright 2024 Sadek, Shib, Taher, Rashed, Shukry, Atia, Taymour, El-Nablaway, Ibrahim, Ramadan, Abdelkader, Abdo, Imbrea, Pet, Ali and Abdeen